Research compendium
Amycretin
Amycretin is designed to act at GLP-1 and amylin receptors within one peptide molecule. Early documentation examines different formulations. The ingredient name alone does not identify the preparation, population or experimental question behind a result.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
What is established and what remains a hypothesis
Keep source limits and editorial status visible. A proposed mechanism should not be presented as a confirmed property in every context.
- Is the source the original work, a review or a later interpretation?
- Has the observation been reproduced under independent conditions?
- Does the material defined in the paper match the entity named in this entry?
Mechanism described in the literature
Unimolecular distinguishes this design from a two-ingredient combination. It implies neither equal contributions to each endpoint nor interchangeable exposure between oral and subcutaneous formulations.
Classification
Unimolecular GLP-1 and amylin receptor agonist peptide
Other names
- Amycretin
What the first oral study examined
The first-in-human trial enrolled adults with overweight or obesity across several experimental parts. Safety and tolerability were primary, accompanied by pharmacokinetics and pharmacodynamic observations. Exploratory weight changes were recorded, but treating them as definitive confirmation would omit the early-stage design’s purpose.
What the subcutaneous formulation added
The phase 1b/2a study also prioritized adverse events and examined exposure and weight. Weight differences versus placebo were observed, with predominantly gastrointestinal events. Withdrawals and different durations across study parts must accompany interpretation of estimates.
What these articles do not compare
The publications are not a direct formulation comparison. Contrasting figures without accounting for population, duration, exposure and dropout can create a ranking neither study tested. Identify the evaluated preparation and its primary endpoint first.
Questions and answers
Is amycretin a mixture of two peptides?
Not as described in these studies. It is one molecular agonist with two receptor targets.
Can results transfer between formulations?
Not automatically. A shared ingredient does not establish equivalent exposure, tolerability or response; each preparation needs specific data.
Sources
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial — Lancet (2025); PMID 40550229; DOI 10.1016/S0140-6736(25)01176-6
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial — Lancet (2025); PMID 40550229; DOI 10.1016/S0140-6736(25)01176-6
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Lancet (2025); PMID 40550231; DOI 10.1016/S0140-6736(25)01185-7
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Lancet (2025); PMID 40550231; DOI 10.1016/S0140-6736(25)01185-7